article thumbnail

RNA that doesn't age

Science Daily: Pharmacology News

Certain RNA molecules in the nerve cells in the brain last a life time without being renewed. RNAs are generally short-lived molecules that are constantly reconstructed to adjust to environmental conditions. Neuroscientists have now demonstrated that this.

RNA 342
article thumbnail

Researchers develop RNA-targeting technology for precisely manipulating parts of human genes

Science Daily: Pharmacology News

Researchers have harnessed a bacterial immune defense system, known as CRISPR, to efficiently and precisely control the process of RNA splicing.

RNA 280
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New imaging method enables detailed RNA analysis of the whole brain

Science Daily: Pharmacology News

Researchers have developed a groundbreaking microscopy method that enables detailed three-dimensional (3D) RNA analysis at cellular resolution in whole intact mouse brains. The new method, called TRISCO, has the potential to transform our understanding of brain function, both in normal conditions and in disease, according to the new study.

RNA 260
article thumbnail

Startup AIRNA emerges from stealth to bring RNA editing to a rare disease

BioPharma Drive: Drug Pricing

AIRNA is one of several biotechs to debut plans for target alpha-1 antitrypsin deficiency in recent years, with competitors such as AlveoGene, Wave Life Sciences and Arrowhead Pharmaceuticals.

RNA 310
article thumbnail

Roche bets on Ionis RNA medicines with neuroscience deal

BioPharma Drive: Drug Pricing

The Swiss drugmaker is restocking its pipeline by buying into preclinical Ionis medicines for Alzheimer’s and Huntington’s diseases.

RNA 297
article thumbnail

Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases

BioPharma Drive: Drug Pricing

billion, is the latest research collaboration involving small molecule drugs that modify RNA. The deal, which could be worth up to $1.8

RNA 164
article thumbnail

Novartis buys a preclinical biotech and its RNA drug technology

BioPharma Drive: Drug Pricing

For $500 million, Novartis will acquire DTx Pharma and its preclinical neurological disease drugs, marking the Swiss company’s latest investment in gene-silencing medicines.

RNA 246